Sanofi SA

Press Release: Myqorzo and Redemplo approved in China

15 Jan 2026 01:00:00 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - December 2025

14 Jan 2026 12:30:00 By Nasdaq GlobeNewswire

Press Release: Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes

12 Jan 2026 01:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes

05 Jan 2026 01:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline

24 Dec 2025 01:15:00 By Nasdaq GlobeNewswire

Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis

24 Dec 2025 01:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia

23 Dec 2025 09:06:55 By Nasdaq GlobeNewswire

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma

23 Dec 2025 01:00:00 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - November 2025

22 Dec 2025 12:35:00 By Nasdaq GlobeNewswire

Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation

19 Dec 2025 14:21:48 By Nasdaq GlobeNewswire

Press release: Availability of the Q4 2025 Aide memoire

17 Dec 2025 01:30:00 By Nasdaq GlobeNewswire

Press Release: Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema

17 Dec 2025 01:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis

15 Dec 2025 01:05:00 By Nasdaq GlobeNewswire

Press Release : Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis

15 Dec 2025 01:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases

11 Dec 2025 01:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi completes acquisition of Vicebio

04 Dec 2025 05:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

25 Nov 2025 01:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes

14 Nov 2025 06:30:00 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares – October 2025

13 Nov 2025 12:30:00 By Nasdaq GlobeNewswire

Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

07 Nov 2025 08:00:00 By Nasdaq GlobeNewswire